The development of mutant P53 characterized by lung cancers contributes to their primary and acquired multi-drug resistance to chemotherapy

J. Xu, C. Z. Zhou, T. Wang, C. H. Du, N. S. Zhong (Guangzhou, China)

Source: Annual Congress 2005 - Gene expression, receptors and markers in lung cancer
Session: Gene expression, receptors and markers in lung cancer
Session type: Poster Discussion
Number: 2921
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Xu, C. Z. Zhou, T. Wang, C. H. Du, N. S. Zhong (Guangzhou, China). The development of mutant P53 characterized by lung cancers contributes to their primary and acquired multi-drug resistance to chemotherapy. Eur Respir J 2005; 26: Suppl. 49, 2921

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 231s
Year: 2002

The effect of new drug-resistance antisense gene on multidrug resistance mechanism of drug-resistant human small cell lung cancer cells
Source: Eur Respir J 2007; 30: Suppl. 51, 715s
Year: 2007

The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance
Source: Annual Congress 2005 - Prognostic factors in lung cancer
Year: 2005


Relationship between mutated P53 and the acquired multi-drug resistance after cisplatin selection in NCI-H460 cell line of human large cell lung cancer
Source: Annual Congress 2004 - Molecular biology
Year: 2004


Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy
Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer
Year: 2019



The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI
Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD
Year: 2019



Clone and initial identification of differentially expressed genes of human small-cell lung cancer multi-drug resistance cell line
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007


The role of Pgp, MRP and LRP expression in chemotherapy response of small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 78s
Year: 2004

P-glycoprotein (p-gp) and lung resistance protein (lrp), as predictive factors of response to platinum-based chemotherapy for lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 231s
Year: 2001

ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer
Source: Annual Congress 2005 - Prognostic factors in lung cancer
Year: 2005


A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018



Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs?
Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research
Year: 2021


Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
Source: Eur Respir J 2011; 37: 624-631
Year: 2011



The biology of lung cancer
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61
Year: 2001

p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009

A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells
Source: Eur Respir J 2006; 28: Suppl. 50, 853s
Year: 2006

p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
Source: Annual Congress 2007 - Novel genetic markers in pathology
Year: 2007


The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule
Source: Annual Congress 2009 - Pathogenesis of lung cancer
Year: 2009

Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010